241 assets in Parkinson Disease

Therapeutic assets addressing Parkinson Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fexofenadine Parkinson Disease	Tanta University	P2/3	CCC (50)
Haescs Parkinson Disease	Shanghai East Hospital	P1	CCC (50)
Montelukast Parkinson Disease	Mostafa Bahaa	P2/3	CCC (50)
Vinpocetine Parkinson Disease	Tanta University	P2/3	CCC (50)
Aci-7104.056 Parkinson Disease	AC Immune SA	P2	CCC (48)
ap-472 Parkinson Disease	Appello Pharmaceuticals, Inc.	P2	CCC (48)
av-101 Parkinson Disease	VistaGen Therapeutics, Inc.	P2	CCC (48)
Bhv-8000 Parkinson Disease	Biohaven Therapeutics Ltd.	P2/3	CCC (48)
Dapansutrile Parkinson Disease	Cambridge University Hospitals NHS Foundation Trust	P2	CCC (48)
Dopamine Parkinson Disease	University Hospital, Lille	P1/2	CCC (48)
Doxycycline Parkinson Disease	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	P2	CCC (48)
ec5026 Parkinson Disease	EicOsis Human Health Inc.	P1/2	CCC (48)
Etoricoxib Parkinson Disease	Ihab Elsayed Hassan	P2	CCC (48)
Exidavnemab Parkinson Disease	BioArctic AB	P2	CCC (48)
Folic Acid Parkinson Disease	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	P2	CCC (48)
Gemfibrozil Parkinson Disease	Forest Hills Lab	P2	CCC (48)
Hbi-002 Parkinson Disease	Hillhurst Biopharmaceuticals, Inc.	P2	CCC (48)
Human Allogeneic Induced Pluripotent Stem Cell -Derived Dopaminergic Neural Progenitor Cell Parkinson Disease	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	P1/2	CCC (48)
Mirtazapine Parkinson Disease	Leila Dargahi. PharmD PhD	P2	CCC (48)
Neu-411 Parkinson Disease	Neuron23 Inc.	P2	CCC (48)
Nevadistinel Parkinson Disease	Aptinyx	P2	CCC (48)
Pirepemat Parkinson Disease	Integrative Research Laboratories AB	P2	CCC (48)
Radotinib Parkinson Disease	Il-Yang Pharm. Co., Ltd.	P2	CCC (48)
Rndp-001 Parkinson Disease	Kenai Therapeutics	P1/2	CCC (48)
Sargramostim Parkinson Disease	University of Nebraska	P1	CCC (48)
Sfx-01 (Sulforaphane Stabilized With .Alpha. Cyclodextrin) Parkinson Disease	Central South University	P2	CCC (48)
Silymarin Parkinson Disease	Tanta University	P2	CCC (48)
Tocovid Suprabio Parkinson Disease	National Neuroscience Institute	P2	CCC (48)
Valiloxybate Parkinson Disease	XWPharma	P2	CCC (48)
XJN010 Parkinson Disease	Guangzhou Novaken Pharm Co., Ltd.	P2	CCC (48)
hnc364 Parkinson Disease	Guangzhou Henovcom Bioscience Co. Ltd.	P1	CC (47)
irl757 Parkinson Disease	Integrative Research Laboratories AB	P1/2	CC (47)
Tenapanor Parkinson Disease	Cedar Valley Digestive Health Center	P2	CC (47)
Vgn-R08B Parkinson Disease	Shanghai Vitalgen BioPharma Co., Ltd.	P1/2	CC (47)
Allogenic Embryonic Stem Cell-Derived A9 Dopamine Progenitor Cell Parkinson Disease	S.Biomedics Co., Ltd.	P1/2	CC (46)
Butyrin Parkinson Disease	Prabesh Kanel	P1/2	CC (46)
Dpa-714 Parkinson Disease	University of Alabama at Birmingham	P1/2	CC (46)
Sirolimus Parkinson Disease	Royan Institute	P1/2	CC (46)
18f-op-801 Parkinson Disease	Ashvattha Therapeutics, Inc.	P1/2	CC (45)
Midodrine Parkinson Disease	Vanderbilt University Medical Center	P1	CC (45)
Amdx-2011P Parkinson Disease	Amydis Inc.	P1/2	CC (44)
Azd-0328 Parkinson Disease	King's College London	P2	CC (44)
Her-096 Parkinson Disease	Herantis Pharma Plc.	P1	CC (44)
Hypoestoxide Parkinson Disease	University of Ibadan	P1/2	CC (44)
PE 2I Parkinson Disease	Universitaire Ziekenhuizen KU Leuven	P1/2	CC (44)
ub-312 Parkinson Disease	NYU Langone Health	P1	CC (44)
Adipose-Derived Mesenchymal Stem Cells Parkinson Disease	Taiwan Mitochondrion Applied Technology Co., Ltd.	P1	CC (43)
Aln-Snca Parkinson Disease	Regeneron Pharmaceuticals	P1	CC (43)
Dopacell Parkinson Disease	Royan Institute	P1	CC (43)
Dsp-1083 Implantation Parkinson Disease	Sumitomo Pharma America, Inc.	P1/2	CC (43)

Showing 101 to 150 of 241 assets

PreviousPage 3 of 5Next